Ludesi 2DGE Analysis Service Improves Discovery Potential in Proteomics
News Jun 12, 2007
Ludesi AB has announced results demonstrating that its technology significantly improves discovery potential in 2D gel electrophoresis based on data from its growing customer list of global research institutes, pharmaceutical companies, and universities.
According to Company, the Ludesi 2DGE Image Analysis Service offers two advantages for scientists over existing 2DGE image analysis software solutions. First, because it is a service, scientists and researchers don’t have to purchase software, be trained, or spend valuable time manually manipulating software to try and obtain good results. Second, the Ludesi solution consistently improves the number of correctly-identified protein regulations over existing software packages and reduces the false discovery rate.
Ludesi guarantees to generate more true hits and fewer false positives than a customer’s current solution or there is no charge. Improved protein regulation detection may generate new scientific findings and productivity in the research areas of biomarkers and drug discovery.
“The Ludesi service consistently saves time for scientists and dramatically improves the discovery potential in 2D gel electrophoresis for our customers”, stated Ola Forsstrom-Olsson, founder and CEO of Ludesi AB. “The conventional way of performing 2D gel image analysis is a well-known bottleneck and is holding back the true potential of this key proteomics technology. Instead, we believe it should be hassle-free and time-efficient to get scientifically reliable results.”
In a Poster Created by Johns Hopkins University and presented at the PepTalk Conference in January 2007 the impact of image analysis accuracy on results and discovery potential in 2D gel electrophoresis was investigated. The poster presented results from a variety of gels that were analyzed with two of the leading software products currently available on the market and
Ludesi. The poster can be viewed and downloaded at: http://www.ludesi.com/downloads/ludesi-peptalk-poster-2007-01-04.pdf.
Current Ludesi Customers Include: Academy of Sciences, Czech Republic; DSM Nutritional Products, Switzerland; Johns Hopkins Proteomics Center, USA; Karolinska Institute, Sweden; Mitsubishi Pharma, Japan; NIH, National Eye Institute, USA; NIH, Critical Care, USA; NIH, Nuclear Medicine, USA.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.